CytoDyn, Inc.

Footnotes and statements below graphics cannot absolve the problems raised by misleading claims in an promotional piece, the US Food and Drug Administration told AstraZeneca PLC in a rare warning le

Pharmaceutical companies that want to use influencers to promote their products should provide compliance training on US Food and Drug Administration promotional requirements, ensure the content conve

New molecular entities had a rough week at the US FDA, as the agency issued a complete response letter for Gilead Sciences, Inc. ’s bulevirtide for hepatitis delta virus infection, CytoDyn, Inc. wi

Althera Pharmaceuticals Inc. touted the ability of Roszet (rosuvastatin/ezetimibe) to reduce LDL-C levels from 64% to 72% in a promotional sheet to doctors. But the US Food and Drug Administration ob